Summary Although the presence of axillary node metastases in breast cancer is a key prognostic indicator and may influence treatment decisions, a significant proportion of patients diagnosed as axillary node negative (ANN) using standard histopathological techniques may have occult nodal metastases (OMs). A combination of limited step-sectioning (4 x 100 /im intervals) and immunohistochemical staining (with cytokeratin (MNF.116) and MUCI (BC2) antibodies) was used to detect OM in a retrospective series of 208 ANN patients. OMs were found in 53 patients (25%), and both step-sectioning and immunohistochemical detection significantly improved detection (P<0.05). Detection using BC2 (25%) was superior to MNF. 116 (18%) and haematoxylin and eosin (H&E) (8%). OMs were found in 51 patients using only the first and deepest sectioning levels and BC2 staining. OMs were more frequently found in lobular (38%) than ductal carcinoma (25%), and more frequently in women less than 50 years (41%) than in older women (19%). Univariate overall and disease-free survival analyses showed that the presence, size and number of OM had prognostic significance as did tumour size (disease-free only) and histological and nuclear grade (P>0.05). Cox multivariate proportional hazard regression analyses showed that the presence and increasing size of OMs were significantly associated with poorer disease-free survival, independently of other prognostic factors (P>0.05). However there was not a significant independent association of the presence of occult metastases with overall survival (P =0.11). These findings have important implications with regard to selection of ANN patients for adjuvant therapy.
Several large clinical trials have illustrated the survival benefits of adjuvant endocrine or chemotherapeutic treatments in patients with axillary node-negative (ANN) breast cancer (Fisher and Redmond, 1992; Stewart, 1992) . However, as only about 30% of this subgroup of patients will eventually develop recurrent disease, adjuvant treatment of all node-negative patients represents excessive treatment of a majority of these patients. Prognostic factors are clearly required to help stratify these patients into risk groups as the basis for decision-making regarding the provision of adjuvant treatment. Factors considered to have potential clinically useful prognostic importance in ANN breast cancer include tumour size, tumour grade, ploidy, presence of oestrogen receptors, overexpression of oncogenes such as c-erbB-2 and epidermal growth factor receptor (EGFR), altered expression of tumoursuppressor genes such as p53 and Rbl, and increased expression of molecules involved in invasion and metastasis such as cathepsin D (for a review, see McGuire et al., 1992) .
While all of these factors have been demonstrated to have prognostic importance, no single variable clearly stratifies patients into risk groups, and therefore clinical decisions must be made giving consideration to multiple factors.
The presence of axillary node metastases is accepted as a key prognostic indicator in breast cancer (Nemoto et al., 1980) , yet is has been recognised for some time that a significant proportion of patients diagnosed as node negative using standard histopathological techniques may in fact have nodal metastases. However, the proportion of ANN patients with these occult metastases, the best practical way of detecting them, and the prognostic significance of these metastases remain unclear. There are two main sources of error in the current histopathological examination of axillary lymph nodes for the detection of metastases. The first involves sampling error attributable to the sectioning procedure and is related to the size of the node, the orientation of the node in the sectioning block, the size and location of any metastases, and the number of sections examined (Wilkinson and Hause, 1974) . The second involves microscopic misdiagnosis of sectioned metastases, which is related to the size and location of the metastases and the morphology of the lesions and surrounding nodal tissue.
Strategies for reducing sectioning error that have been tested include macroscopic sectioning of large nodes before blocking (de Mascarel et al., 1992) and serial or stepsectioning through routinely prepared blocks [Wilkinson et al., 1982; Friedman et al., 1988; International (Ludwig) Breast Cancer Study Group, 1990] . Strategies for reducing microscopic misdiagnosis that have been tested include using immunohistochemical techniques to highlight metastases (Wells et al., 1984) . More recently, a technique using reverse transcriptase-polymerase chain reaction (RT-PCR) to detect expression of tumour-associated antigen mRNA extracted from axillary nodes has been tested as an alternative to histopathological examination (Noguchi et al., 1994) .
However, using either serial sectioning or immunohistochemical detection in isolation ignores the alternative source of error in diagnosis. For example, in a Ludwig Breast Cancer Study Group examination of lymph nodes from 921 patients using a laborious serial sectioning procedure examining 36 sections from each block, only 9% of patients were found to have metastases [International (Ludwig) Breast Cancer Study Group, 1990 ]. This proportion is equal to or less than that found by many trials using a more practical strategy of immunohistochemical detection in a single section (Wells et al., 1984; Trojani et al., 1987a; Raymond and Leong, 1989; Galea et al., 1991; Byrne et al., 1992; Elson et al., 1993; Hainsworth et al., 1993) . Despite its apparently high detection rate, immunohistochemical detection in a single section ignores the reality of sampling error. A recent study using a combination of step-sectioning and immunohistochemical detection found metastases in 31% of 159 ANN patients (Nasser et al., 1993 Group, 1990] , although these findings differ from those of two earlier large studies using similar techniques (Wilkinson et al., 1982; Friedman et al., 1988 Ackerman and Rosai (1974) . Small nodes were included without dissection, and large nodes were multiply sliced before embedding. Nodes were generally not processed singly but grouped according to level in the axilla. However, some variation in adherence to these methods could have occurred over the period of this study. These procedures were performed before the development of the current UK guidelines for pathological assessment of axillary nodes. Axillary metastases were not found in any of these patients on routine histopathological assessment of a single haematoxylin and eosin (H&E)-stained section from each block. Patients were included in the study only after conforming with the following selection criteria: an axillary dissection comprising at least five lymph nodes (median= 12; range 5 -32) and a minimum of 5 years follow-up if not deceased of breast cancer (the median follow-up of these patients was 92 months; range 59-235). Patients in the study group had a median age of 59 years (range 26 -84) .
One consultant histopathologist (RGW) reviewed the original H&E-stained slide of all primary tumours to confirm the diagnosis. The tumours were graded according to the Nottingham modification of the Bloom and Richardson system . Three tumours were not graded because the infiltrating component was present as multifocal minimal invasion in a larger area of in situ disease.
In 13 cases asynchronous bilateral primary breast tumours occurred, and in five of these cases both primary tumours were included in the study. However, for the purposes of survival analysis, the patient was included using data for the first tumour only. Patients who subsequently developed a second primary with involvement of the contralateral axillary lymph nodes were treated as censored observations for survival analysis at the time of diagnosis of the second primary. 
Immunohistochemistry
Sections were dewaxed and rehydrated to distilled water through descending graded alcohols, then transferred to 0.1 M phosphate-buffered saline (PBS), pH 7.4. Sections to be stained for cytokeratins were subjected to enzymatic digestion using 0.1% trypsin, 0.1% calcium chloride in PBS for 30 min at 37°C. Endogenous peroxidase activity was quenched by incubating the sections in 0.3% hydrogen peroxide, 18% methanol in PBS for 10 min. After thorough washing in PBS, sections were immersed in 4% commercial non-fat skim milk powder in PBS for 15 min to inhibit nonspecific antibody binding, before being transferred to a humidified chamber and covered with 10% normal (nonimmune) goat serum for 20 min. Excess serum was decanted from the sections and the primary antibody applied. The antibodies were diluted 1 7000 in PBS containing 10% nonimmune sheep serum for BC2 mouse ascites and 1:100 for MNF. 1 16. The sections were incubated with the primary antibody for 45 min at room temperature. Following this and subsequent incubations, the sections were washed thoroughly in three changes of PBS for 5 min each. In the case of BC2, the first wash contained 1% v/v Triton X-100. Sections for cytokeratins were then incubated for 30 min with prediluted biotinylated goat anti-mouse immunoglobulin buffer (Zymed, San Francisco, CA USA), then streptavidin-biotin-horseradish peroxidase conjugate (Zymed) diluted 1: 20 in PBS for 15 min. Sections being stained with BC2 were subsequently incubated with biotinylated sheep anti-mouse immunoglobulin (Amersham Australia, Sydney, Australia) diluted 1: 150 in PBS followed by a 1:150 dilution in PBS of streptavidinhorseradish peroxidase (Amersham). Antigenic sites were revealed by incubating sections in 0.05% 3,3'-diaminobenzene in 0.1 M Tris-buffered saline with hydrogen peroxide as substrate. After washing in gently running tap water, the sections were counterstained with haematoxylin, dehydrated through graded alcohols, cleared in xylene, and mounted with DePeX. Sections of human primary breast cancer were run with each batch of immunohistochemical stains to act as positive controls. Figure 1 . Most metastases (28, 53%) were confined to the capsule or subcapsular space (Figure la and b) with 13 (25%) confined to the node parenchyma and 12 (23%) involving both the subcapsular space and nodal parenchyma. Many metastases in the nodal parenchyma presented as scattered tumour cells rather than solid metastases ( Figure Ic  and d) . Seven of the nine cases with large scattered deposits (> 1 mm diameter) in the nodal parenchyma were infiltrating lobular carcinoma (ILC) (24% of cases of this histological type) compared with only two of infiltrating ductal carcinoma (IDC) (1% of these cases). The number of nodes involved and the size of metastases are detailed in Tables II and III respectively. In most cases (75%) only one node was involved and in 79% of cases the metastases were less than 1 mm in diameter. The detection rates in cases classified according to histological type, tumour size, histological grade, menopausal status and age are shown in Table IV . Occult metastases were more frequently found in premenopausal and younger women, and in patients with larger primary tumours. There was also a trend toward a higher frequency of occult metastases in ILC than in IDC, and only one of 16 cases of other histological type had occult metastases detected.
The number of cases with metastases detected using each of the staining techniques and each of the four sectioning levels are detailed in Table V . Detection with either antibody was significantly superior to detection with H&E-stained sections at all sectioning levels (P< 0.05). The overall proportion of cases with occult metastases was greater using detection with the BC2 monoclonal antibody reactive with MUCI than using the cytokeratin-reactive antibody MNF.116, although this difference just failed to reach statistical significance (0.05 <P <0.06). Metastases detected in 15 patients using BC2 were not detected using MNF.116, but only in one case was a metastasis detected in a patient using MNF. 116 but not with BC2. Reappraisal of the MUCI-positive/cytokeratin-negative metastases showed these stained either very weakly or not at all with MNF.116 (Figure le and f) . Interestingly, the number of cases with metastases detected using either immunohistochemical technique was equivalent at each sectioning level but the number of cases detected at deeper levels was significantly greater when using H&E detection (level 1 vs level 4, P <0.02). Combining data from all four levels gave an increased detection rate over that for level one alone for all staining techniques, although this difference was not statistically significant for cytokeratin detection. It can be seen in Table V that combining levels one and four (the first and deepest levels) gave virtually identical detection rates to those obtained using all four levels for each of the three staining techniques.
Specificity of immunohistochemical detection
All immunohistochemically detected cells were checked for morphological features consistent with adenocarcinoma before verification as a metastatic deposit. In two cases isolated immunohistochemically detected cells were present that were unable to be confirmed as tumour cells and were therefore considered equivocal and these nodes were classified as being tumour free. In several cases isolated normal lymphoid cells were positive using the BC2 antibody but these cells were easily recognised as such and after confirmation of this finding by consensus review by two pathologists (MCC and RGW) were disregarded. Five benign naevi were detected in this series; none of these were positive for either cytokeratins or MUC1. One benign epithelial inclusion was detected and this was positive for both MUCI and cytokeratins. Tumour size and histological and nuclear grade were also of prognostic importance; these variables were combined along with patient age and histological type with data concerning detection of occult metastases in multivariate proportional hazards regression analyses. The presence of metastases (P=0.093), their size (P=0.221) and the number of nodes involved (P= 0.244) were not shown to be statistically significant independent predictors of overall survival at the 95% level. However, the presence (P=0.036) and increasing size of metastases (P = 0.037) were significantly associated with poorer disease-free survival, independently of other considered prognostic factors. Relative hazard rates for the model using presence/size of metastases are shown in Table VII . A simple index was constructed using the sum of coded data from tumour size (0, <20 mm diameter; 1, >20 mm), histological grade (0, grade 1; 1, grades 2 and 3) and presence/size of occult metastases (0, absent; 1, <0.5 mm; 2, >0.5 mm). Figure 3 illustrates the progressively poorer disease-free survival of patients with increasing index scores. Particularly striking was the completely diseasefree survival of the 35 patients with small, low-grade tumours and no occult metastases (index score 0).
Discussion
The results of this study confirmed the predicted sources of error in standard pathological assessment of axillary lymph nodes with both immunohistochemical detection and stepsectioning resulting in increased detection of metastases. A technique which is practical and relatively inexpensive to implement, that is obtaining two sections 300 gm apart and staining with one antibody, resulted, in this study, in the detection of occult metastases in 25% of apparently nodenegative patients. The presence of these metastases was associated with poorer disease-free and overall survival, and was of independent prognostic significance for disease-free survival to other significant variables including tumour size and histological grade. Furthermore, we have demonstrated that metastases in these immunohistochemical sections can be detected by adequately trained scientific staff, which would minimise the workload of specialist pathologists and therefore reduce the cost of implementing such procedures.
The detection of occult metastases in 25% of cases of ANN breast cancer is higher than that found in most previous studies designed to detect these metastases [Wilkinson et al., 1982; Wells et al., 1984; Trojani et al., 1987a; Raymond and Leong, 1989 ; International (Ludwig) Breast Cancer Study Group, 1990; Nio et al., 1990; Galea et al., 1991; Byrne et al., 1992; Elson et al., 1993; Hainsworth et al., 1993] . However, the only other study to simultaneously address both sources of error in the standard histopathological technique found metastases in 31% of 159 ANN patients (Nasser et al., 1993) . Furthermore, the findings in the current study of metastases in 8% of cases using four sectioning levels and H&E detection and 13% of cases using immunohistochemical detection of cytokeratins in a single section are similar to those data found in earlier studies using comparable techniques.
The superior detection of metastases using the MUC1-reactive antibody BC2 compared with the cytokeratin antibody MNF. 116 was unexpected. Two previous studies comparing two different cytokeratin antibodies (CAM5.2 and AE1/AE3) with two different MUCI antibodies (NCRC11 and DF3) found the cytokeratin antibodies to be at least as good as the MUC1 antibodies for the detection of metastatic deposits (Galea et al., 1991; Elson et al., 1993) . The decreased staining efficiency with the cytokeratin antibody in the present study appears to be related to loss of expression of cytokeratins or to difficulty of detection as, unlike mucin detection with BC2, the detection with MNF. 116 requires a trypsinisation step to reveal these epitopes. Positive control breast cancer sections were included in each staining run and were always positive using MNF. 116. Staining of primary aPositive using at least one stain. al., 1993; Nasser et al., 1993) . The higher rate of detection of occult metastases in lobular compared with ductal carcinoma confirms the findings of Trojani et al., (1987a) . Metastatic lobular carcinoma appears more likely to present as occult deposits of scattered cells within the nodal parenchyma than metastatic ductal carcinoma. In the present study these scattered deposits were often quite large and they obviously present a diagnostic difficulty using H&E due to morphological similarities with surrounding cells in the lymph node. Consistent with this hypothesis, the large Ludwig group study based on serial sectioning and H&E detection showed an equivalent rate of detection of metastases from IDC and ILC. The results of this study clearly show poorer disease-free and overall survival in patients with occult metastases. These data also support the findings of previous studies using immunohistochemical detection that showed that the size of occult metastases and number of nodes involved have prognostic importance (Hainsworth et al., 1993; Nasser et al., 1993) . Although the number of cases of ILC in this study is quite small, the survival results from this group do not contradict the findings of a previous study with more patients with ILC that found that occult metastases had little prognostic significance in ILC (Trojani et al., 1987a) . The differences in survival between patients with ILC and IDC who also have occult metastases may reflect biological differences consistent with their different patterns of metastatic spread characterised by Harris et al. (1984) . The independent significance of the presence/size of occult metastases suggests that this factor could be combined with other more traditionally used prognostic factors when assessing the risk of recurrence or death of patients with apparently node-negative breast cancer. The simple index created from presence/size of occult metastases, histological grade and tumour size suggests that these patients could well be stratified into prognostic groups that may be used for determining and tailoring adjuvant systemic treatments in this group of patients traditionally regarded as node negative and in whom the selection of patients truly requiring systemic treatment has formerly been difficult. It may be that in the future that such an index including detection of occult metastases could be combined with biological markers of poor prognosis such as alterations in tumour-suppressor genes and increased expression of oncogenes. We shall be examining the associations of such factors in these patients in the near future. Detection of metastatic tumour cells in bone marrow of breast cancer patients is now also feasible and may have prognostic significance (Cote et al., 1991; Dearnaley et al., 1991) , and could also be combined into a risk index.
We have demonstrated a high rate of occult metastases in patients with ANN breast cancer and have shown that these metastases can be detected using practical and affordable variations to standard histopathological techniques. The presence of these metastases is an independent indicator of poor prognosis and therefore should be considered for inclusion into indices used to stratify ANN patients into risk groups for consideration for adjuvant therapy. gratitude is extended to Dianna Battistuta for statistical advice and particularly for performing the Cox multivariate regression analyses. 
